Fingolimod Hydrochloride

盐酸芬戈莫德

Report date: 2026/03/31 20:00:21
NMEFirst In Class

Base Information

Drug NameFingolimod Hydrochloride
Drug Alias Name盐酸芬格莫德Fingolimodum盐酸芬戈莱默盐酸芬戈利德芬戈莫德 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSphingosine 1-phosphate receptor 4 modulatorsSphingosine 1-phosphate receptor 3 modulatorsSphingosine 1-Phosphate Receptor 1 modulators +[4] 
TargetsSphingosine 1-phosphate receptor 3Sphingosine 1-Phosphate Receptor 1Sphingosine 1-phosphate receptor 4 +[4] 
Therapy Area/IndicationsRejection of renal transplantationHemorrhagic StrokeSchizophrenia +[23] 
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaMultiple Sclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date2010/09/21
Country/TerritoryCzechiaBelgiumBulgaria +[52] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma KkWake Forest University Health SciencesNovartis Pharma Schweiz Ag +[8] 
Inactive CompaniesGenuine Research Center, EgyptAls Therapy Development InstituteCharite University, Berlin, Germany +[9] 
Active IndicationsHemorrhagic StrokeIntracranial Hemorrhage, HypertensiveCerebral Hemorrhage +[9] 
Inactive IndicationsRejection of renal transplantationSchizophreniaPain +[14] 

Other Information

ATC CodeL04AE01
Related LinksWikipediaDrugBankKEGG